Buserelin Acetate (Suprefact®)

Buserelin Acetate (SuCommon name: Buserelin Acetate
Brand name: Suprefact®


What is Buserelin Acetate?

Buserelin Acetate is a luteinizing hormone releasing hormone (LHRH) analogue that is used in the palliative treatment of advanced (metastatic) prostate cancer. Buserelin acetate works by blocking the production of testosterone which reduces the growth and reproduction of prostate cancer cells.
 

How is Buserelin Acetate administered?

Buserelin Acetate is by administered by subcutaneous injection or as a nasal solution.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received buserelin acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Diarrhea
  • Dizziness
  • Dry mouth
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Reduced sexual desire (low libido)


Is Buserelin Acetate covered in my province or territory?*

Buserelin acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
Buserelin acetate is not covered by provincial drug programs in:
  • Prince Edward Island


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=6447


    
Last Reviewed: July 2017

 
   
   




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive